JAGUAR HEALTH, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
JAGUAR HEALTH, INC. (JAGX) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $4.92 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-19
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.92M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$15.75M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$18.69M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.36M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-06-30 | $4.92M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | -$15.75M 10-Q · filed 2026-08-19 | |
| 2025-12-31 | -$18.69M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $4.36M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $6.88M 10-Q · filed 2026-08-19 | |
| 2025-03-31 | $830.00K 10-Q · filed 2026-08-19 | |
| 2024-12-31 | $6.49M 10-Q · filed 2026-08-19 | |
| 2024-09-30 | $13.10M 10-Q · filed 2025-11-14 | $13.10M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $16.58M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $11.82M 10-Q · filed 2025-08-14 | $11.82M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.90M 10-K · filed 2026-04-07 | |
| 2023-09-30 | $1.42M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $5.83M 10-Q · filed 2024-11-13 | $5.83M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $7.66M 10-Q · filed 2024-08-13 | |
| 2022-12-31 | -$1.36M 10-K · filed 2025-03-31 | -$1.36M 10-K · filed 2023-03-24 |
| 2022-09-30 | $3.60M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $2.76M 10-Q · filed 2023-11-14 | $2.76M 10-Q · filed 2022-08-22 |
| 2022-03-31 | $8.11M 10-Q · filed 2023-08-14 | $8.11M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $11.85M 10-K · filed 2024-04-01 | |
| 2021-09-30 | $21.55M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $31.79M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $31.89M 10-Q · filed 2022-08-22 | |
| 2020-12-31 | $17.20M 10-K · filed 2023-03-24 | |
| 2019-12-31 | $10.67M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |